Cardiovascular Risk Factor and Atherosclerosis in Rheumatoid Arthritis (RA).

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Cardiology Reports Pub Date : 2025-01-20 DOI:10.1007/s11886-025-02198-8

Lakshmi Kattamuri, Shivangini Duggal, John Paul Aparece, Shrilekha Sairam

{"title":"Cardiovascular Risk Factor and Atherosclerosis in Rheumatoid Arthritis (RA).","authors":"Lakshmi Kattamuri, Shivangini Duggal, John Paul Aparece, Shrilekha Sairam","doi":"10.1007/s11886-025-02198-8","DOIUrl":null,"url":null,"abstract":"Purpose of review: To highlight advancements in managing traditional and rheumatoid arthritis (RA) specific risk factors and the impact of RA treatments on cardiovascular outcomes.Recent findings: Advancements in rheumatoid arthritis management have paralleled declining trends in cardiovascular disease risks. Biomarkers like CRP, Lipoprotein(a), Apolipoprotein B 100, and imaging tools such as coronary artery calcium scoring enhance cardiovascular risk stratification, particularly in intermediate-risk RA patients. While effective RA treatments, have demonstrated substantial cardiovascular benefits, subclass differences were noted in high-risk patients. Increased risk of cardiovascular disease is driven by chronic inflammation, altered lipid metabolism, and traditional risk factors. Effective RA treatment significantly lowers cardiovascular events. Standard treatment of hypertension, diabetes and hypercholesterolemia are effective and lowers RA disease activity and inflammatory markers. While RA is considered a risk enhancing state in calculating CV risk scores, currently there exists no RA disease -specific blood pressure, blood sugar or lipid targets.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"31"},"PeriodicalIF":3.1000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cardiology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11886-025-02198-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To highlight advancements in managing traditional and rheumatoid arthritis (RA) specific risk factors and the impact of RA treatments on cardiovascular outcomes.

Recent findings: Advancements in rheumatoid arthritis management have paralleled declining trends in cardiovascular disease risks. Biomarkers like CRP, Lipoprotein(a), Apolipoprotein B 100, and imaging tools such as coronary artery calcium scoring enhance cardiovascular risk stratification, particularly in intermediate-risk RA patients. While effective RA treatments, have demonstrated substantial cardiovascular benefits, subclass differences were noted in high-risk patients. Increased risk of cardiovascular disease is driven by chronic inflammation, altered lipid metabolism, and traditional risk factors. Effective RA treatment significantly lowers cardiovascular events. Standard treatment of hypertension, diabetes and hypercholesterolemia are effective and lowers RA disease activity and inflammatory markers. While RA is considered a risk enhancing state in calculating CV risk scores, currently there exists no RA disease -specific blood pressure, blood sugar or lipid targets.

查看原文本刊更多论文

类风湿关节炎（RA）的心血管危险因素和动脉粥样硬化。

综述的目的：强调传统和类风湿性关节炎（RA）特定危险因素的管理进展，以及RA治疗对心血管结局的影响。最近发现：类风湿关节炎管理的进步与心血管疾病风险的下降趋势平行。生物标志物如CRP、脂蛋白(a)、载脂蛋白b100和成像工具如冠状动脉钙评分可增强心血管风险分层，特别是在中度风险RA患者中。虽然有效的类风湿性关节炎治疗已显示出实质性的心血管益处，但在高危患者中注意到亚类差异。心血管疾病的风险增加是由慢性炎症、脂质代谢改变和传统危险因素驱动的。有效的类风湿性关节炎治疗可显著降低心血管事件。高血压、糖尿病和高胆固醇血症的标准治疗是有效的，可以降低RA疾病的活动性和炎症标志物。虽然在计算心血管风险评分时，RA被认为是一种风险增强状态，但目前还没有RA疾病特异性的血压、血糖或血脂指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Cardiology Reports CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

6.20

自引率

2.70%

发文量

209

期刊介绍： The aim of this journal is to provide timely perspectives from experts on current advances in cardiovascular medicine. We also seek to provide reviews that highlight the most important recently published papers selected from the wealth of available cardiovascular literature. We accomplish this aim by appointing key authorities in major subject areas across the discipline. Section editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.